TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34286513

Group type: EXPERIMENTAL
Intervention: Serum soluble Sdc1 levels in active UC group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serum soluble Sdc1 levels in inactive UC group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of Sdc1 with severity of UC (Mayo score)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ROC analysis of Sdc1 with endoscopic Mayo score ≥2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cutoff value of Sdc1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Panel of biomarkers including CRP, hemoglobin, hematocrit, and Sdc1
Number of subjects: 0
Study: 34286512

Group type: EXPERIMENTAL
Intervention: More home visits (5 studies, 2102 women)
Number of subjects: 12080

Group type: COMPARATOR
Intervention: Fewer home visits (2 studies, 862 women)
Number of subjects: 12080

Group type: EXPERIMENTAL
Intervention: More home visits (4 studies, 1365 infants)
Number of subjects: 12080

Group type: EXPERIMENTAL
Intervention: More home visits (3 studies, 960 women)
Number of subjects: 12080

Group type: EXPERIMENTAL
Intervention: Individualised care by midwives (1 study, 1295 women)
Number of subjects: 12080

Group type: EXPERIMENTAL
Intervention: Home visits (3 studies, 2368 women)
Number of subjects: 12080

Group type: EXPERIMENTAL
Intervention: Home visits (1 study, 513 women)
Number of subjects: 12080

Group type: COMPARATOR
Intervention: Home visits vs. facility-based care (3 studies, 3257 women)
Number of subjects: 12080
Study: 34286624

Group type: EXPERIMENTAL
Intervention: Family function, perceived support, and caregiver burden measured at four different time points over one year.
Number of subjects: 0
Study: 34286638

Group type: EXPERIMENTAL
Intervention: GnRH analogue with fermented wheat germ extract (FWGE) for at least 4 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: GnRH analogue
Number of subjects: 36
Study: 34286886

Group type: EXPERIMENTAL
Intervention: Pharmacy administration and dispensing of methadone for MMT (5-160 mg/day for 3 months)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pharmacy administration and dispensing of methadone for MMT
Number of subjects: 20
Study: 34287023

Group type: EXPERIMENTAL
Intervention: Sertraline; specific dosage and duration not available
Number of subjects: 0
Study: 34287217

Group type: EXPERIMENTAL
Intervention: Community-based screening using an oral fluid-based rapid test (OFT)
Number of subjects: 1907

Group type: COMPARATOR
Intervention: Standard of care with web-based data collection system
Number of subjects: 1907
Study: 34287262

Group type: EXPERIMENTAL
Intervention: Changing the time of day for taking endocrine therapy (tamoxifen and/or aromatase inhibitors)
Number of subjects: 0
Study: 34287805

Group type: EXPERIMENTAL
Intervention: Pamiparib (PARTRUVIX™; BeiGene Ltd.)
Number of subjects: 0
Study: 34287942

Group type: EXPERIMENTAL
Intervention: Lanadelumab 300 mg q2wks
Number of subjects: 212
Study: 34288026

Group type: EXPERIMENTAL
Intervention: One dose of post-transplant cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34288223

Group type: EXPERIMENTAL
Intervention: Severe irritability group (n=46)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Healthy youths group (n=62)
Number of subjects: 108
Study: 34288271

Group type: EXPERIMENTAL
Intervention: Medical therapy (levodopa)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Subthalamic nucleus deep brain stimulation
Number of subjects: 28
Study: 34288547

Group type: EXPERIMENTAL
Intervention: Rabeprazole (PPI)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lorlatinib oral solution
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 27
Study: 34288560

Group type: EXPERIMENTAL
Intervention: Single crown/bridge rehabilitation
Number of subjects: 58

Group type: COMPARATOR
Intervention: All-on-4 rehabilitation
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: HIV-positive patients population
Number of subjects: 58
Study: 34288738

Group type: EXPERIMENTAL
Intervention: AFFIRM questionnaire (33-item patient-reported outcome measure)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: AFFIRM-A
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: AFFIRM-U
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: AFFIRM questionnaire
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Reported symptoms
Number of subjects: 102
Study: 34289017

Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg/d) and ulocuplumab (cycles 1 to 6, 4 weeks each)
Number of subjects: 13
Study: 34289231

Group type: EXPERIMENTAL
Intervention: Cytoreductive radical prostatectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 80
Study: 34289656

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m2 (single dose) and oral prednisone (for at least 5 days) prior to chemoimmunotherapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rituximab/prednisone prephase treatment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Prephase treatment
Number of subjects: 33
Study: 34289815

Group type: EXPERIMENTAL
Intervention: HGS weakness (HGSw)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non-HGS weakness (non-HGSw)
Number of subjects: 43
Study: 34289829

Group type: EXPERIMENTAL
Intervention: Cardiac symptoms
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: Nursing care dependency
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: Unemployment
Number of subjects: 1435
Study: 34289977

Group type: EXPERIMENTAL
Intervention: Lung Clearance Index (LCI)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Forced Expired Volume in 1 second (FEV)
Number of subjects: 237
Study: 34290067

Group type: EXPERIMENTAL
Intervention: Awake mapping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asleep mapping
Number of subjects: 0

Group type: COMPARATOR
Intervention: No mapping
Number of subjects: 0
Study: 34290403

Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 0
Study: 34291073

Group type: EXPERIMENTAL
Intervention: Adherence to a healthy lifestyle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34291312

Group type: EXPERIMENTAL
Intervention: Children diagnosed before 6 years of age
Number of subjects: 8502

Group type: COMPARATOR
Intervention: Children diagnosed at 6-13 years of age
Number of subjects: 8502

Group type: EXPERIMENTAL
Intervention: Initial seroconversion before 2 years of age
Number of subjects: 8502

Group type: EXPERIMENTAL
Intervention: Initial seroconversion after 2 years of age
Number of subjects: 8502

Group type: EXPERIMENTAL
Intervention: Minor alleles of rs1004446 (INS)
Number of subjects: 8502

Group type: EXPERIMENTAL
Intervention: Minor alleles of rs2476601 (PTPN22)
Number of subjects: 8502

Group type: EXPERIMENTAL
Intervention: Minor alleles of rs428595 (PPIL2)
Number of subjects: 8502

Group type: EXPERIMENTAL
Intervention: Minor alleles of rs113306148 (PLEKHA1)
Number of subjects: 8502

Group type: EXPERIMENTAL
Intervention: Minor alleles of rs73043122 (RNASET2)
Number of subjects: 8502
Study: 34291470

Group type: EXPERIMENTAL
Intervention: Adhesive composite restorations
Number of subjects: 87
Study: 34291703

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) laser treatment, 3 sessions over 20 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Histological analysis after CO2 laser treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Immunohistochemical analysis after CO2 laser treatment
Number of subjects: 14
Study: 34291810

Group type: EXPERIMENTAL
Intervention: Patients admitted during the third pandemic wave
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Patients admitted before February 1, 2021
Number of subjects: 1829
Study: 34291813

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant
Number of subjects: 18

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 18
Study: 34291850

Group type: EXPERIMENTAL
Intervention: preAD
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CIs
Number of subjects: 62

Group type: COMPARATOR
Intervention: NCs
Number of subjects: 62
Study: 34291990

Group type: EXPERIMENTAL
Intervention: Hamilton Anxiety Inventory (HAM-A)
Number of subjects: 0
Study: 34292174

Group type: EXPERIMENTAL
Intervention: Selective RET-inhibitors (selpercatinib and pralsetinib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mutational analysis combined with cytological assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigation of immune-based therapy
Number of subjects: 0
Study: 34292185

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-α
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TGF-β1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-existing pain condition (yes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peritraumatic life stress (higher levels)
Number of subjects: 0
Study: 34292214

Group type: EXPERIMENTAL
Intervention: First dose of CoronaVac vaccine
Number of subjects: 0
Study: 34292324

Group type: EXPERIMENTAL
Intervention: Anthracycline-based regimens
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Consolidative autologous stem cell transplant (ASCT) in first complete remission (CR1)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Age ≥60 years, ECOG performance status >2, elevated C-reactive protein, elevated β2 microglobulin
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: AITL score (novel prognostic score)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: POD24 (progression of disease within 24 months)
Number of subjects: 282
Study: 34292473

Group type: EXPERIMENTAL
Intervention: Chronic tonsillitis group
Number of subjects: 46

Group type: COMPARATOR
Intervention: Tonsillar hypertrophy group
Number of subjects: 46
Study: 34292516

Group type: EXPERIMENTAL
Intervention: Propofol sedation (0.03 mg/kg)
Number of subjects: 80
Study: 34292537

Group type: EXPERIMENTAL
Intervention: Ba-Duan-Jin (BDJ) exercise and placebo capsule
Number of subjects: 104

Group type: COMPARATOR
Intervention: Pregabalin capsule and wellness education with guided muscle-relaxation exercises
Number of subjects: 104
Study: 34292891

Group type: EXPERIMENTAL
Intervention: Subjective refraction (SR)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Autorefraction (AR)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Wavefront aberrometry (WA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Partial least squares regression and random forest regression
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Astigmatic vectors
Number of subjects: 90
Study: 34293119

Group type: EXPERIMENTAL
Intervention: Convalescent plasma with high neutralizing antibody titers
Number of subjects: 25
Study: 34293201

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy with concurrent doxorubicin (CC-IMRT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intensity-modulated radiation therapy alone (IMRT)
Number of subjects: 27
Study: 34293369

Group type: EXPERIMENTAL
Intervention: Spontaneous closure
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Assisted closure
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 201
Study: 34293527

Group type: EXPERIMENTAL
Intervention: Single-dose L-theanine
Number of subjects: 0
Study: 34293726

Group type: EXPERIMENTAL
Intervention: Synthetic pulmonary perfusion images from 4DCT using deep learning
Number of subjects: 0
Study: 34293802

Group type: EXPERIMENTAL
Intervention: Lanreotide autogel
Number of subjects: 80
Study: 34294152

Group type: EXPERIMENTAL
Intervention: Collagen scaffold/umbilical cord mesenchymal stem cells (CS/UC-MSCs)
Number of subjects: 18
Study: 34294637

Group type: EXPERIMENTAL
Intervention: Noninvasive keratograph break-up time (NIKBUT)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Tear break-up time (TBUT)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Schirmer test
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Tear meniscus height (TMH)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Bulbar redness (BR)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Ocular Surface Disease Index (OSDI) scores
Number of subjects: 288
Study: 34294862

Group type: EXPERIMENTAL
Intervention: SYNB1618 (engineered bacterial therapeutic)
Number of subjects: 0
Study: 34295186

Group type: EXPERIMENTAL
Intervention: Naldemedine 0.2 mg
Number of subjects: 2336

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2336
Study: 34295813

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy with intensity-modulated radiation therapy (IMRT) at a total dose of 40 Gy in 20 fractions.
Number of subjects: 70
Study: 34296150

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA for 20 min per session, 10 sessions total)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 31
Study: 34296321

Group type: EXPERIMENTAL
Intervention: Maternal vitamin B supplementation
Number of subjects: 4746
Study: 34296417

Group type: EXPERIMENTAL
Intervention: Moxidectin 8 mg fixed-dose
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Moxidectin weight-based dosing
Number of subjects: 96
Study: 34296427

Group type: EXPERIMENTAL
Intervention: Prophylactic corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Earlier corticosteroid and tocilizumab intervention
Number of subjects: 0
Study: 34296522

Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous semaglutide for weight management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IWQOL-Lite-CT composites
Number of subjects: 0
Study: 34296674

Group type: EXPERIMENTAL
Intervention: Non-pharmaceutical interventions (NPI)
Number of subjects: 0
Study: 34296962

Group type: EXPERIMENTAL
Intervention: β-TI patients
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hs-CRP
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 45
Study: 34297046

Group type: EXPERIMENTAL
Intervention: Azacitidine (75 mg/m2) administered IV once daily on days 1 to 7 of a 28-day cycle
Number of subjects: 18
Study: 34297062

Group type: EXPERIMENTAL
Intervention: Malaria in pregnancy (MiP) at least once
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Placental malaria diagnosed by qPCR
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: High parasite density at delivery
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Malaria at second antenatal care visit
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: High parasite density at second antenatal care visit
Number of subjects: 493
Study: 34297159

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAP-100
Number of subjects: 0
Study: 34297259

Group type: EXPERIMENTAL
Intervention: Online training system with a 32-exercise training course providing online instruction (about 15 min/week) in 13 core family therapy techniques.
Number of subjects: 48
Study: 34297797

Group type: EXPERIMENTAL
Intervention: Administration of IGF-1 to old mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Administration of anti-TNF-α antibodies to human patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peripheral B cells producing TNF-α
Number of subjects: 0
Study: 34297969

Group type: EXPERIMENTAL
Intervention: Midurethral sling operation
Number of subjects: 100
Study: 34298149

Group type: EXPERIMENTAL
Intervention: Hypophosphatemic patients with acute liver failure (ALF)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Normophosphatemic patients with acute liver failure (ALF)
Number of subjects: 76
Study: 34298376

Group type: EXPERIMENTAL
Intervention: Recommended treatments (R-T) for first-line (1L) patients
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Non-recommended treatments (NR-T) for first-line (1L) patients
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Recommended treatments (R-T) for pre-treated (2L+) patients
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Non-recommended treatments (NR-T) for pre-treated (2L+) patients
Number of subjects: 1500
Study: 34298554

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 1709
Study: 34298589

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2080

Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 2080

Group type: COMPARATOR
Intervention: Fish oil
Number of subjects: 2080

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 2080

Group type: COMPARATOR
Intervention: Dipyridamole
Number of subjects: 2080

Group type: COMPARATOR
Intervention: Dipyridamole plus aspirin
Number of subjects: 2080

Group type: COMPARATOR
Intervention: Low-intensity warfarin
Number of subjects: 2080

Group type: COMPARATOR
Intervention: Sulphinpyrazone
Number of subjects: 2080

Group type: COMPARATOR
Intervention: GTN patch
Number of subjects: 2080
Study: 34298717

Group type: EXPERIMENTAL
Intervention: Targeted methylation cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test
Number of subjects: 6200
Study: 34300020

Group type: EXPERIMENTAL
Intervention: Educational videos on Pediatric Obesity Management using the five As (Ask, Assess, Advise, Agree, Assist)
Number of subjects: 0
Study: 34300133

Group type: EXPERIMENTAL
Intervention: Home smoking ban
Number of subjects: 202

Group type: COMPARATOR
Intervention: Inconsistent home smoking ban
Number of subjects: 202

Group type: COMPARATOR
Intervention: No home smoking ban
Number of subjects: 202
Study: 34300217

Group type: EXPERIMENTAL
Intervention: Abnormal urinalysis
Number of subjects: 145

Group type: COMPARATOR
Intervention: Normal urinalysis
Number of subjects: 145
Study: 34300338

Group type: EXPERIMENTAL
Intervention: PiCCO cannula for three days
Number of subjects: 23

Group type: COMPARATOR
Intervention: PiCCO cannula for five days
Number of subjects: 23
Study: 34300402

Group type: EXPERIMENTAL
Intervention: BLE beacon-based algorithm for remote measurement of social behavior
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BLE beacon sensors setup by participants/caregivers
Number of subjects: 0
Study: 34301173

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 1622

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 1622

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1622

Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 1622
Study: 34301221

Group type: EXPERIMENTAL
Intervention: CXD101
Number of subjects: 51
Study: 34301237

Group type: EXPERIMENTAL
Intervention: Dental caries data registered at an examination
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Dental caries data from patient dental record
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Dental caries data from SKaPa registry
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficient (ICC) between researcher and patient journal
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficient (ICC) between patient dental record and SKaPa
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficient (ICC) between researcher and SKaPa
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: SKaPa registry information
Number of subjects: 170
Study: 34301246

Group type: EXPERIMENTAL
Intervention: Wearable device capable of detecting and reversing overdose
Number of subjects: 97
Study: 34301273

Group type: EXPERIMENTAL
Intervention: High HEI tertile
Number of subjects: 365

Group type: COMPARATOR
Intervention: Low HEI tertile
Number of subjects: 365
Study: 34301808

Group type: EXPERIMENTAL
Intervention: Pacmilimab 10 mg/kg + Ipilimumab 3 mg/kg administered every 3 weeks
Number of subjects: 27
Study: 34301809

Group type: EXPERIMENTAL
Intervention: Pacmilimab at a recommended phase 2 dose (RP2D) of 10 mg/kg administered intravenously every 14 days
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Pacmilimab at RP2D of 10 mg/kg
Number of subjects: 114
Study: 34301810

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 116
Study: 34302257

Group type: EXPERIMENTAL
Intervention: Mediastinal shift angle (MSA)
Number of subjects: 0
Study: 34302290

Group type: EXPERIMENTAL
Intervention: Ceftazidime 40 mg/kg IV q6h (max 8 g/day)
Number of subjects: 29
Study: 34302517

Group type: EXPERIMENTAL
Intervention: Management of arterial partial pressure of carbon dioxide (PaCO2)
Number of subjects: 1100
Study: 34302533

Group type: EXPERIMENTAL
Intervention: Imatinib-pioglitazone regimen
Number of subjects: 10

Group type: COMPARATOR
Intervention: Imatinib monotherapy
Number of subjects: 10
Study: 34302589

Group type: EXPERIMENTAL
Intervention: Eribulin 1.4 mg/m² in combination with trastuzumab and pertuzumab (HP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eribulin 1.4 mg/m²
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genomic alterations
Number of subjects: 0
Study: 34302711

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34302748

Group type: EXPERIMENTAL
Intervention: Micronutrient powders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34302760

Group type: EXPERIMENTAL
Intervention: Bictegravir, emtricitabine, and tenofovir alafenamide (single-tablet regimen)
Number of subjects: 102
Study: 34302788

Group type: EXPERIMENTAL
Intervention: Polyomavirus-specific T cells infusion
Number of subjects: 12
Study: 34302856

Group type: EXPERIMENTAL
Intervention: zWFL
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: zBMI
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: zWFL and zBMI
Number of subjects: 464
Study: 34303017

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 1314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1314
Study: 34303860

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34304148

Group type: EXPERIMENTAL
Intervention: Nexus Narcolepsy Registry participants
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Pediatric symptom onset
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Overall mean time from symptom onset to diagnosis
Number of subjects: 1024
Study: 34304385

Group type: EXPERIMENTAL
Intervention: IDegAsp
Number of subjects: 236
Study: 34304968

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day for up to 3 years, in addition to ongoing corticosteroid treatment.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Corticosteroids only (historical control).
Number of subjects: 13
Study: 34305401

Group type: EXPERIMENTAL
Intervention: Higher TyG Index (tertiles)
Number of subjects: 1432